Jacky Smith, ATS 2021: Findings from the COUGH-1 and COUGH-2 Study Data
We were delighted to talk with Professor Jacky Smith (School of Biological Sciences, The University of Manchester, Manchester, UK) around cough frequency with gefapixant in patients with chronic cough.
The abstract ‘Objective Cough Frequency with Gefapixant in Chronic Cough: A Pooled Analysis of Two Phase 3 Randomized, Controlled Clinical Trials (COUGH-1 and COUGH-2).’ was presented at ATS 2021 International Conference, 14-19 May, 2021.
- What are the greatest challenges in the management of people with chronic cough? (0:17)
- What is the rationale for the use of gefapixant in the treatment of chronic cough? (1:52)
- Could you tell us a little about the COUGH-1 and COUGH-2 studies? (3:09)
- What were the findings of the pooled analysis of the COUGH-1 and COUGH-2 study data? (5:03)
- What will be the likely place of gefapixant in the treatment paradigm for chronic cough? (6:02)
Disclosures: Jacky Smith discloses consultancy work and delivery of clinical trials for Merck, Bayer, Bellus Health and Shionogi. Collaboration with Vitalograph Ltd and License agreement between Vitalograph and hospital, who receive royalties.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ATS 2021 (Virtual).
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!